NZ611614A - Compositions and methods for treating amyloid plaque associated symptoms - Google Patents
Compositions and methods for treating amyloid plaque associated symptomsInfo
- Publication number
- NZ611614A NZ611614A NZ611614A NZ61161411A NZ611614A NZ 611614 A NZ611614 A NZ 611614A NZ 611614 A NZ611614 A NZ 611614A NZ 61161411 A NZ61161411 A NZ 61161411A NZ 611614 A NZ611614 A NZ 611614A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compositions
- associated symptoms
- methods
- amyloid plaque
- plaque associated
- Prior art date
Links
- 208000024891 symptom Diseases 0.000 title abstract 3
- 208000037259 Amyloid Plaque Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41906010P | 2010-12-02 | 2010-12-02 | |
| US201161548542P | 2011-10-18 | 2011-10-18 | |
| PCT/US2011/063121 WO2012075422A2 (en) | 2010-12-02 | 2011-12-02 | Compositions and methods for treating amyloid plaque associated symptoms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ611614A true NZ611614A (en) | 2015-07-31 |
Family
ID=46172597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ611614A NZ611614A (en) | 2010-12-02 | 2011-12-02 | Compositions and methods for treating amyloid plaque associated symptoms |
Country Status (14)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2847218A4 (en) * | 2012-05-08 | 2015-12-30 | Univ Ramot | APOE4 ANTIBODY FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
| CA2962969C (en) | 2014-09-30 | 2023-03-21 | Washington University | Tau kinetic measurements |
| WO2017192711A1 (en) * | 2016-05-03 | 2017-11-09 | University Of South Florida | Compositions and methods of modulating abeta protein |
| WO2018081642A1 (en) | 2016-10-28 | 2018-05-03 | Washington University | Anti-apoe antibodies |
| JP7280238B2 (ja) * | 2017-07-17 | 2023-05-23 | ヤンセン バイオテツク，インコーポレーテツド | フィブロネクチンｉｉｉ型ドメインに対する抗原結合領域及びその使用方法 |
| AU2020282792B2 (en) * | 2019-05-28 | 2025-12-04 | Banner Health | ApoE antibodies, fusion proteins and uses thereof |
| EP4419552A4 (en) * | 2021-10-19 | 2025-09-24 | Bioatla Inc | CONDITIONALLY ACTIVE PROTEINS FOR NEURODEGENERATIVE DISEASES |
| AU2023399623A1 (en) * | 2022-11-30 | 2025-07-03 | Bio-Techne Corporation | Natural killer cell engagers |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2142300C (en) * | 1992-10-13 | 2005-08-23 | Allen D. Roses | Methods for detecting alzheimer's disease |
| EP1687336A2 (en) * | 2003-11-28 | 2006-08-09 | AstraZeneca AB | Antibodies |
| AU2005228764A1 (en) * | 2004-03-30 | 2005-10-13 | Renomedix Institute Inc. | Remedy for prion disease and method of producing the same |
| CA2643048A1 (en) * | 2006-02-21 | 2007-08-30 | Oklahoma Medical Research Foundation | Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor |
| CA2672581A1 (en) * | 2006-12-14 | 2008-06-19 | Forerunner Pharma Research Co., Ltd. | Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same |
| CL2008002775A1 (es) * | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| CA2791648A1 (en) * | 2010-03-01 | 2011-09-09 | The J. David Gladstone Institutes | Antibody specific for apolipoprotein and methods of use thereof |
-
2011
- 2011-12-02 EP EP11844128.6A patent/EP2646053A4/en not_active Withdrawn
- 2011-12-02 CN CN2011800667946A patent/CN103338786A/zh active Pending
- 2011-12-02 US US13/990,777 patent/US20140037638A1/en not_active Abandoned
- 2011-12-02 JP JP2013542218A patent/JP2014502276A/ja active Pending
- 2011-12-02 KR KR1020137016719A patent/KR20140017513A/ko not_active Withdrawn
- 2011-12-02 MX MX2013006116A patent/MX2013006116A/es not_active Application Discontinuation
- 2011-12-02 SG SG2013042288A patent/SG190952A1/en unknown
- 2011-12-02 NZ NZ611614A patent/NZ611614A/en not_active IP Right Cessation
- 2011-12-02 AU AU2011336360A patent/AU2011336360A1/en not_active Abandoned
- 2011-12-02 BR BR112013013723A patent/BR112013013723A2/pt not_active IP Right Cessation
- 2011-12-02 WO PCT/US2011/063121 patent/WO2012075422A2/en not_active Ceased
- 2011-12-02 CA CA2819679A patent/CA2819679A1/en not_active Abandoned
- 2011-12-02 RU RU2013130002/10A patent/RU2013130002A/ru not_active Application Discontinuation
-
2013
- 2013-05-31 ZA ZA2013/03996A patent/ZA201303996B/en unknown
-
2016
- 2016-08-22 US US15/243,495 patent/US20160355581A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN103338786A (zh) | 2013-10-02 |
| BR112013013723A2 (pt) | 2019-09-24 |
| WO2012075422A2 (en) | 2012-06-07 |
| US20160355581A1 (en) | 2016-12-08 |
| CA2819679A1 (en) | 2012-06-07 |
| ZA201303996B (en) | 2015-10-28 |
| EP2646053A2 (en) | 2013-10-09 |
| EP2646053A4 (en) | 2014-05-28 |
| MX2013006116A (es) | 2013-10-17 |
| AU2011336360A1 (en) | 2013-07-04 |
| KR20140017513A (ko) | 2014-02-11 |
| RU2013130002A (ru) | 2015-01-10 |
| US20140037638A1 (en) | 2014-02-06 |
| WO2012075422A3 (en) | 2012-10-04 |
| SG190952A1 (en) | 2013-07-31 |
| JP2014502276A (ja) | 2014-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ611614A (en) | Compositions and methods for treating amyloid plaque associated symptoms | |
| CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
| UA108198C2 (uk) | Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування | |
| MY163521A (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| WO2012062925A3 (en) | Compounds and methods for treating pain | |
| WO2013061161A3 (en) | New combination therapies for treating neurological disorders | |
| EA201001771A1 (ru) | Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью | |
| MX355543B (es) | Macrociclos peptidomiméticos. | |
| WO2012173846A3 (en) | Peptidomimetic macrocycles | |
| SG179095A1 (en) | Novel assay for the detection of amyloid beta peptides | |
| MX355606B (es) | Método in vitro para determinar el potencial miope de un paciente. | |
| MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
| IN2015DN00370A (cg-RX-API-DMAC7.html) | ||
| WO2012112315A3 (en) | Methods for diagnosis of kawasaki disease | |
| MX360554B (es) | Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2. | |
| IN2014DN08385A (cg-RX-API-DMAC7.html) | ||
| WO2012019054A3 (en) | Expression of antibody or a fragment thereof in lactobacillus | |
| MX359930B (es) | Uso de ácido siálico, precursor de ácido siálico o una combinación de los anteriores para preparar medicamentos útiles en una condición diabética o síndrome nefrótico. | |
| IN2015DN03969A (cg-RX-API-DMAC7.html) | ||
| MA32416B1 (fr) | 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation | |
| PH12013502563A1 (en) | Dha and epa in the reduction of oxidative stress | |
| SG194235A1 (en) | Methods of predicting the development of complement-mediated disease | |
| WO2009098355A8 (en) | Novel use of probiotics | |
| MX364626B (es) | Péptidos miméticos. | |
| WO2009059239A3 (en) | REDUCING Aβ42 LEVELS AND Aβ AGGREGATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 DEC 2016 BY CPA GLOBAL Effective date: 20151222 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 DEC 2017 BY CPA GLOBAL Effective date: 20161021 |
|
| LAPS | Patent lapsed |